Serum thrombospondin-2 is a candidate diagnosis biomarker for early non-small-cell lung cancer. Issue 7 (26th July 2019)

• Record Type: Journal Article
• Authors: Jiang, Yi-ming; Yu, Dan-lu; Hou, Guo-xin; Jiang, Jia-lu; Zhou, Qiang; Xu, Xiao-fang
• Is Part Of: Bioscience reports. Volume 39:Issue 7(2019)
• Publication Date: 2019-07-26
• Subjects: Biomarker -- Diagnosis -- NSCLC -- Serum -- THBS2; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20190476
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract : Thrombospondin-2 (THBS2) is a secreted protein overexpressed in numerous cancers and may function as a diagnostic tumor marker. The objective of the present study was to investigate the diagnostic performance of serum THBS2 in early stage non-small-cell lung cancer (NSCLC). Serum THBS2 and Cyfra21-1 level were evaluated in blood samples of 112 patients from NSCLC groups and 51 healthy control (HC) groups. Receiver operator characteristic (ROC) curves were used to evaluate the diagnostic significance. Serum THBS2 level was significantly up-regulated in NSCLC patients compared with healthy control subjects ( P <0.0001), and the postoperative THBS2 level decreased significantly ( P <0.0001). ROC curves analysis demonstrated that THBS2 was a comparable biomarker as Cyfra21-1 to distinguish early stage NSCLC or lung squamous cell carcinoma (SC) from healthy control subjects. And Cyfra21-1 was observed with significantly improved performances by the combination of THBS2 to distinguish early stage NSCLC ( P <0.05) as well as SC ( P <0.05) from the control subjects. In addition, THBS2 was estimated to perform well in the diagnosis of patients with Cyfra21-1-negative NSCLC (area under the curve [AUC] = 0.73). In summary, the present study suggested that serum THBS2 might be an early diagnostic biomarker for NSCLC.